Emergent Bioslutions has been awarded a contract worth up to $186.5 million dollars to devlop the next generation of anthrax vaccine for the federal government.
The contract is with the Department of Health and Human Services for the development of a recombinant protective antigen anthrax vaccine.
Company Spokesman Mark Alley says the new contract will mean an additional 25 jobs at the Lansing plant.
Emergent Chairman and chief executive officer Fuad El-Hibri says the new agreement "solidifies Emergent's anthrax francise and reaffirms our position as the leading supplier to, and developer for, the U.S. government of anthrax biomedical countermeasures."
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.